Key Highlights
- ARK Invest offloaded 50,312 shares of Rocket Lab valued at approximately $4 million via ARKQ ETF on April 27
- The transaction represents ARK’s second Rocket Lab divestment within days, following a prior sale of 113,000+ shares
- ARK purchased 263,848 shares of Intellia Therapeutics totaling roughly $3.6 million through ARKK and ARKG funds
- The firm divested 13,806 Iridium Communications shares valued at approximately $538,000
- Rocket Lab stock gained 3.28% on Monday, finishing at $82.29 despite ARK’s exit
Cathie Wood’s investment management firm, ARK Invest, executed multiple portfolio adjustments on Monday, April 27, 2026, as revealed in the company’s routine fund disclosure reports.
The most significant transaction involved divesting 50,312 shares of Rocket Lab through the ARKQ exchange-traded fund, representing approximately $4.01 million in value. This divestment occurred merely days following ARK’s disposal of more than 113,000 shares of the identical stock during the preceding Friday.
The consecutive sales within such a compressed timeframe indicate ARK is intentionally reducing its exposure to the space technology firm.
The noteworthy aspect of this transaction is that Rocket Lab’s stock experienced a 3.28% increase on Monday, settling at $82.29. ARK chose to sell during a positive momentum phase rather than during a downturn.
The investment firm seems to be capitalizing on gains in anticipation of Rocket Lab’s first quarter 2026 financial results, scheduled for release on May 7, 2026.
Financial analysts on Wall Street anticipate Rocket Lab will report quarterly revenues reaching $189.65 million, representing a 55% increase compared to the previous year. Analysts also forecast a loss of $0.07 per share, showing improvement from the $0.12 loss per share recorded during the corresponding quarter last year.
ARK Increases Investment in Intellia Therapeutics
While reducing its Rocket Lab holdings, ARK aggressively accumulated Intellia Therapeutics stock. The firm acquired 263,848 shares distributed between its ARKK and ARKG ETFs, totaling approximately $3.6 million.
Intellectia specializes in gene-editing technology, and its shares declined 4.33% during Monday’s trading session. ARK evidently capitalized on this price reduction as an entry point.
This strategy aligns with ARK’s established approach of increasing positions during temporary price declines in companies it considers promising long-term growth investments.
Additionally, ARK disposed of 13,806 shares of Iridium Communications through its ARKX ETF, totaling roughly $538,000. This transaction continues an ongoing pattern — ARK previously sold 33,315 Iridium shares the prior Friday and 81,422 shares during the Monday before that.
Wall Street Perspective on Rocket Lab
Notwithstanding ARK’s selling activity, at least one prominent Wall Street analyst maintains an optimistic outlook on Rocket Lab.
Stifel analyst Erik Rasmussen elevated his price target for the stock to $105 from $90 and maintained a Buy recommendation. He highlighted consistent revenue expansion, a robust project pipeline, and the anticipated debut of the Neutron rocket during the current year.
Based on TipRanks data, Rocket Lab currently maintains a Moderate Buy consensus rating, derived from nine Buy recommendations and four Hold recommendations issued during the previous three months.
The consensus analyst price target stands at $89.00, suggesting approximately 8% potential upside from present trading levels.
ARK’s subsequent daily disclosure will reveal whether the firm continued reducing its Rocket Lab holdings on Tuesday.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
